Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alberto Fresa
Observed names:
A. Fresa,
Fresa, Alberto
Institution:
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Observed institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Centre Hospitalier du Mans,
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale",
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0000-0002-8084-9009
Observed ORCID:
0000-0002-8084-9009
OpenAlex ID:
A5032650523
Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti‐CD19 CAR‐T cells
2022
·
Eugenio Galli
, Federica Sorà
, et al.
·
British Journal of Haematology
·
62
PDF
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review
2021
·
Francesco Autore
, Raffaella Pasquale
, et al.
·
Cancers
·
36
PDF
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
2021
·
Alessandra Tedeschi
, Anna Maria Frustaci
, et al.
·
Blood Advances
·
32
PDF
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
2023
·
Thomas Chatzikonstantinou
, Lydia Scarfò
, et al.
·
EClinicalMedicine
·
29
Role of microRNAs in Chronic Lymphocytic Leukemia
2023
·
Francesco Autore
, Alice Ramassone
, et al.
·
International Journal of Molecular Sciences
·
29
PDF
Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management
2023
·
Eugenio Galli
, Alberto Fresa
, et al.
·
European Journal Of Haematology
·
24
PDF
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study
2021
·
Andrea Visentin
, Francesca Romana Mauro
, et al.
·
American Journal of Hematology
·
23
PDF
Acute graft versus host disease 1976–2020: reduced incidence and predictive factors
2024
·
Alessandra Di Francesco
, Anna Maria Raiola
, et al.
·
Frontiers in Medicine
·
21
PDF
Measurable residual disease in chronic lymphocytic leukemia
2023
·
Giulia Benintende
, Federico Pozzo
, et al.
·
Frontiers in Oncology
·
15
PDF
Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed
2024
·
Alberto Fresa
, Idanna Innocenti
, et al.
·
Cancers
·
14
PDF
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
2022
·
Andrea Visentin
, Francesca Romana Mauro
, et al.
·
Frontiers in Oncology
·
14
PDF
First‐line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real‐life study on 547 patients to evaluate the long‐term efficacy and tolerability of different chemoimmunotherapy strategies
2024
·
Francesco Autore
, A. Tedeschi
, et al.
·
American Journal of Hematology
·
13
Richter transformation in Chronic Lymphocytic Leukemia
2022
·
Idanna Innocenti
, Giulia Benintende
, et al.
·
Hematological Oncology
·
12
VEGF and IL-6 correlation in POEMS: a potential upcoming marker of active disease and early autologous BMT response.
2022
·
Luca Laurenti
, Idanna Innocenti
, et al.
·
Mediterranean Journal of Hematology and Infectious Diseases
·
12
PDF
Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review
2021
·
Alberto Fresa
, Francesco Autore
, et al.
·
Journal of Clinical Medicine
·
12
PDF
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
2022
·
Darko Antic
, Natasa Milic
, et al.
·
Journal of Hematology & Oncology
·
11
PDF
What Does Atypical Chronic Lymphocytic Leukemia Really Mean? A Retrospective Morphological and Immunophenotypic Study
2024
·
Giovanni D’Arena
, Candida Vitale
, et al.
·
Cancers
·
8
PDF
Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics
2022
·
Idanna Innocenti
, Annamaria Tomasso
, et al.
·
Hematological Oncology
·
8
PDF
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
2022
·
Anna Maria Frustaci
, Giovanni Del Poeta
, et al.
·
Therapeutic Advances in Hematology
·
8
Purging with chlorambucil to prevent infusion‐related reaction before obinutuzumab administration: A monocentric pilot experience
2019
·
Francesco Autore
, Alberto Fresa
, et al.
·
Hematological Oncology
·
8
Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma
2022
·
Eugenio Galli
, Federica Sorà
, et al.
·
Bone Marrow Transplantation
·
7
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA: CAR-T and CLL
2024
·
Ugo Testa
, Elvira Pelosi
, et al.
·
Mediterranean Journal of Hematology and Infectious Diseases
·
6
Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia
2021
·
Alberto Fresa
, Francesco Autore
, et al.
·
Hematological Oncology
·
6
Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
2020
·
Francesco Autore
, Idanna Innocenti
, et al.
·
Frontiers in Oncology
·
6
PDF
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
2024
·
Idanna Innocenti
, Antonio Mosca
, et al.
·
HemaSphere
·
5
PDF
Show more works
View as search
Works count:
98
Citation count:
479
H-index:
12
I10-index:
16
Year
Topic
Type